AOD-9604 vs Tesamorelin

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicAOD-9604Tesamorelin
What it is

A synthetic 16-amino-acid fragment of human growth hormone (residues 177 to 191 plus an added tyrosine), according to FDA’s 2024 evaluation.1

A growth hormone-releasing factor (GHRF) analogue. The label states that it binds to and stimulates human GRF receptors with potency similar to the natural hormone.4

FDA status

Not FDA-approved

Not FDA-approved; FDA advised against adding it to the compounding list1,2,3

Not FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.1,3

Is AOD-9604 FDA-approved?

FDA-approved

FDA-approved as Egrifta for HIV-associated abdominal fat4,5

FDA-approved. Drugs@FDA lists Egrifta (first approved November 10, 2010), and the label covers reducing excess abdominal fat in adults with HIV and lipodystrophy. The cited label has no boxed warning.4,5

Is tesamorelin FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.6

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. AOD-9604 is not among them.6,7

Not among the six peptides the policy lists.6

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists AOD-9604 among substances whose nominations were withdrawn, citing possible immune reactions, characterization problems and serious adverse events of unclear cause.3

Not addressed in this profile’s sources.

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study The OPTIONS trial: a randomized, double-blind, placebo-controlled weight-loss trial that enrolled 536 adults, known from company filings; FDA found no published report of its methods and results.1
  • Small, short, or incompletely reported human study Six randomized, placebo-controlled company studies summarized in a 2013 safety publication, which FDA found lacked detail on methods and results.1
  • Animal or laboratory research Rodent studies reporting less fat formation and lower body weight, and rat and monkey toxicology studies with possible effects on bone turnover and the liver, described in FDA’s evaluation.1

Large randomized human trials

  • Large randomized human trial Study 1 (NCT00123253): a randomized, double-blind, placebo-controlled trial in 412 adults with HIV, lipodystrophy and excess abdominal fat, with visceral fat measured by CT scan at 26 weeks.4
  • Large randomized human trial Study 2 (NCT00435136): a randomized, double-blind, placebo-controlled trial of the same design in 404 adults.4
Records collected

0 ClinicalTrials.gov records and 2 PubMed records collected

11 ClinicalTrials.gov records and 21 PubMed records collected

Area of study

Metabolic and weight1

Metabolic and weight4

Latest dated events
  1. FDA’s compounding safety-risk page, as last updated, lists AOD-9604 among withdrawn nominations with safety concerns.3
  2. FDA’s Pharmacy Compounding Advisory Committee votes 12 to 0 against placing AOD-9604 on the list.2
  3. FDA staff date their evaluation recommending against adding AOD-9604 to the 503A bulks list.1
  1. DailyMed publishes the Egrifta SV label version cited on this page.4
  2. FDA approves Egrifta, according to Drugs@FDA.5

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  2. 2
    December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  5. 5
    Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026